Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 16;6(1):e12102.
doi: 10.1002/trc2.12102. eCollection 2020.

Evaluating the Alzheimer's disease data landscape

Affiliations

Evaluating the Alzheimer's disease data landscape

Colin Birkenbihl et al. Alzheimers Dement (N Y). .

Abstract

Introduction: Numerous studies have collected Alzheimer's disease (AD) cohort data sets. To achieve reproducible, robust results in data-driven approaches, an evaluation of the present data landscape is vital.

Methods: Previous efforts relied exclusively on metadata and literature. Here, we evaluate the data landscape by directly investigating nine patient-level data sets generated in major clinical cohort studies.

Results: The investigated cohorts differ in key characteristics, such as demographics and distributions of AD biomarkers. Analyzing the ethnoracial diversity revealed a strong bias toward White/Caucasian individuals. We described and compared the measured data modalities. Finally, the available longitudinal data for important AD biomarkers was evaluated. All results are explorable through our web application ADataViewer (https://adata.scai.fraunhofer.de).

Discussion: Our evaluation exposed critical limitations in the AD data landscape that impede comparative approaches across multiple data sets. Comparison of our results to those gained by metadata-based approaches highlights that thorough investigation of real patient-level data is imperative to assess a data landscape.

Keywords: Alzheimer's disease; FAIR data; biomarker; clinical study; cohort; cohort study; data; data access; data set; data sharing; data viewer; data‐driven; dementia; disease modeling; magnetic resonance imaging; open‐science; patient level data.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Combined ethnoracial diversity found across the investigated AD cohorts. Table S2 shows the individual compositions of each cohort
FIGURE 2
FIGURE 2
Interoperability of AD data sets. A, Availability of data modalities scored based on the defined criteria. The criteria are explained in Supplementary Table 1. B, Equivalence of clinical assessment variables across cohorts. PET = positron emission tomography
FIGURE 3
FIGURE 3
Longitudinal follow‐up as the proportion of participants at study baseline (ie, participants were aligned based on their first visit). A, At least one variable measured. B, CSF amyloid beta. C, MMSE scores. CSF = cerebrospinal fluid. MMSE = Mini Mental State Examination

References

    1. Kalra D. The importance of real‐world data to precision medicine. Per Med. 2019;16(2):79‐82. - PubMed
    1. Birkenbihl C, Emon MA, Vrooman H, et al. Differences in cohort study data affect external validation of artificial intelligence models for predictive diagnostics of dementia‐lessons for translation into clinical practice. EPMA J. 2020;11(3):367‐376. - PMC - PubMed
    1. Fröhlich H, Balling R, Beerenwinkel N, et al. From hype to reality: data science enabling personalized medicine. BMC Med. 2018;16(1):150. - PMC - PubMed
    1. Whitwell JL, Wiste HJ, Weigand SD, et al. Comparison of imaging biomarkers in the Alzheimer disease neuroimaging initiative and the Mayo Clinic Study of Aging. Arch Neurol. 2012;69(5):614‐622. - PMC - PubMed
    1. Ferreira D, Hansson O, Barroso J, et al. The interactive effect of demographic and clinical factors on hippocampal volume: a multicohort study on 1958 cognitively normal individuals. Hippocampus. 2017;27(6):653‐667. - PubMed

Grants and funding

LinkOut - more resources